cite
mazzola
lt
kellycirino
c
diagnost
lassa
fever
viru
genet
divers
pathogen
found
lowresourc
set
diagnost
key
effect
prevent
control
lassa
fever
viru
lasv
r
blueprint
prioriti
pathogen
caus
acut
viral
haemorrhag
fever
current
diagnost
includ
laboratorybas
serolog
nucleic
acid
amplif
test
well
rapid
diagnost
test
challeng
lasv
diagnost
includ
commerci
avail
clinic
valid
panlineag
test
option
pointofcar
test
differenti
agent
caus
similar
symptom
need
improv
test
valid
regul
extern
qualiti
assess
target
product
profil
lasv
diagnost
refin
take
account
need
lassa
fever
viru
lasv
caus
acut
viral
haemorrhag
fever
symptom
similar
seen
ebola
viru
infect
lasv
endem
west
africa
transmit
contact
excret
infect
mastomi
natalensi
rodent
rodent
speci
due
high
fatal
rate
lack
treatment
option
difficulti
prevent
control
lasv
one
highprior
pathogen
includ
r
blueprint
lasv
vaccin
strategi
reli
avail
effect
diagnost
test
current
diagnost
lasv
includ
inhous
commerci
primarili
researchonli
laboratorybas
serolog
nucleic
acid
amplif
test
two
commerci
avail
research
use
rapid
diagnost
test
rdt
number
multiplex
panel
differenti
detect
lasv
infect
endem
diseas
similar
symptom
evalu
howev
number
diagnost
gap
remain
lineag
detect
challeng
due
genom
divers
lasv
panlineag
sensit
molecular
immunolog
detect
necessari
surveil
outbreak
respons
panlineag
elisa
rdt
commerci
avail
research
use
valid
extern
qualiti
assess
eqa
need
confirm
detect
sensit
known
relev
strain
variabl
sensit
lasv
pcr
test
also
highlight
need
improv
valid
eqa
given
lasv
outbreak
typic
occur
lowresourc
set
option
pointofcar
test
would
valuabl
requir
taken
account
target
product
profil
improv
lasv
diagnost
lassa
fever
viru
lasv
caus
acut
viral
haemorrhag
fever
vhf
endem
west
africa
everi
year
approxim
peopl
contract
lasv
peopl
die
infect
recent
outbreak
nigeria
saw
confirm
case
case
fatal
rate
higher
case
fatal
rate
report
potenti
zoonot
human
transmiss
well
difficulti
treatment
prevent
lasv
one
highprior
pathogen
identifi
r
blueprint
june
finalis
lasv
vaccin
strategi
reli
improv
diagnost
test
well
enhanc
surveil
capac
endem
countri
summaris
exist
lasv
diagnost
highlight
remain
research
develop
need
lasv
singlestrand
rna
viru
arenavirida
famili
first
identifi
nigeria
lassa
fever
endem
west
africa
includ
nigeria
sierra
leon
guinea
liberia
benin
ghana
mali
spread
neighbour
countri
figur
area
peopl
admit
hospit
everi
year
lasv
case
also
identifi
germani
netherland
sweden
usa
uk
japan
larg
import
travel
west
africa
long
incub
period
lasv
day
make
one
commonli
export
vhf
countri
outsid
endem
rang
reservoir
mastomi
natalensi
multimamm
rodent
common
rodent
across
african
contin
found
predominantli
rural
area
human
dwell
rodent
show
persist
lasv
infect
larg
unaffect
diseas
shed
viru
excrement
seropreval
report
high
natalensi
popul
recent
rodent
speci
includ
hylomyscu
pamfi
mastomi
erythroleucu
shown
host
lasv
transmiss
human
occur
primarili
contact
infect
rodent
urin
faec
handl
consumpt
infect
rodent
also
pathway
infect
airborn
transmiss
may
occur
aerosolis
rodent
excret
dust
clean
activ
natalensi
rodent
readili
colonis
human
area
food
store
contribut
signific
risk
spillov
especi
commun
poor
sanit
crowd
live
condit
humantohuman
transmiss
less
common
lasv
spread
direct
contact
bodili
secret
person
infect
lassa
fever
present
higher
risk
healthcar
humanitarian
personnel
increas
progress
diseas
increas
viral
load
suspect
sexual
transmiss
risk
lasv
detect
semen
month
past
symptomat
infect
prevent
control
prevent
lassa
fever
reli
promot
good
commun
hygien
reduc
potenti
humanrod
contact
measur
discourag
rodent
includ
store
grain
food
rodentproof
contain
good
hand
food
hygien
dispos
garbag
away
home
maintain
clean
household
trap
rodent
employ
cat
natur
deterr
regular
sustain
environment
sanit
also
need
reduc
rodent
activ
although
rodent
food
sourc
high
percentag
commun
consumpt
discourag
healthcar
set
employ
standard
infect
prevent
control
precaut
care
patient
healthcar
laboratori
worker
handl
lasv
specimen
maximum
biosafeti
level
biolog
contain
condit
possibl
precaut
avail
sampl
may
handl
class
iiiii
biosafeti
cabinet
precaut
earli
detect
critic
lasv
contain
strong
surveil
system
necessari
support
intervent
endem
hot
spot
area
lasv
vhf
partner
support
nation
author
affect
countri
outbreak
prepared
emerg
respons
outbreak
detect
shown
recent
outbreak
nigeria
clinic
indic
manag
earli
detect
lasv
infect
difficult
clinic
cours
highli
variabl
symptom
rang
day
postinfect
lassa
fever
symptom
mimic
endem
diseas
malaria
typhoid
fever
vhf
although
bleed
may
help
discrimin
vhf
febril
ill
patient
lassa
fever
present
visibl
bleed
around
peopl
becom
infect
lasv
asymptomat
mild
symptom
gradual
fever
weak
malais
often
go
unreport
day
roughli
infect
progress
headach
sore
throat
cough
muscl
joint
pain
chestabdomin
pain
nausea
vomit
diarrhoea
indic
sever
infect
includ
facial
swell
fluid
lung
caviti
low
blood
pressur
petechia
bruis
hepat
haemorrhag
conjunctiv
gastrointestin
mucos
tissu
critic
ill
case
often
present
acut
respiratori
distress
shock
seizur
tremor
disorient
coma
death
occur
within
day
onset
sever
case
young
peopl
pregnant
women
disproportion
impact
lasv
diseas
especi
seriou
third
trimest
matern
fetal
mortal
reach
rate
respect
nonfat
case
fever
subsid
patient
condit
improv
week
although
renal
damag
along
neurolog
effect
fatigu
persist
sever
week
deaf
common
side
effect
convalesc
phase
typic
accompani
neurolog
dysfunct
vertigo
half
case
hear
return
partial
month
member
arenaviru
famili
compos
ambisens
rna
genom
nucleoprotein
np
surround
lipid
envelop
glycoprotein
lasv
genom
consist
two
singlestrand
rna
segment
small
segment
kb
encod
np
glycoprotein
precursor
gpc
larg
segment
l
kb
encod
rnadepend
rna
polymeras
lp
matrix
protein
z
thought
genet
stabl
consider
genom
variat
detect
geograph
distant
lasv
strain
phenotyp
differ
even
among
close
relat
isol
lasv
phylogeni
far
genet
divers
ebola
viru
sequenc
conserv
lasv
compar
ebola
lasv
compris
least
four
lineag
prototyp
lasv
strain
isol
eastern
nigeria
lineag
strain
isol
southern
central
northern
central
nigeria
lineag
ii
iii
larg
group
guinea
liberia
sierra
leon
lineag
iv
three
distinct
subclad
includ
josiah
strain
fifth
strain
av
lineag
malicot
divoir
propos
figur
well
newli
design
lineag
vi
strain
link
togo
recommend
cours
clinic
manag
lasv
gener
support
care
manag
symptom
approv
antivir
treatment
howev
evid
indic
lassa
respond
ribavirin
administ
earli
onset
symptom
oral
ribavirin
use
postexposur
prophylaxi
person
high
risk
secondari
infect
ribavirin
studi
demonstr
notic
decreas
mortal
sever
case
high
fatal
rate
observ
ribavirintr
untreat
patient
underscor
need
better
lassa
therapeut
favipiravir
anoth
broadspectrum
rna
inhibitor
licens
influenza
broadspectrum
activ
rna
virus
shown
decreas
lassa
viremia
anim
model
small
molecul
benzimidazolerel
scaffold
possess
activ
varieti
arenavirus
interfer
lasv
process
viral
entri
one
compound
assess
anim
model
lassa
fever
lassatr
guinea
pig
exhibit
fewer
sign
diseas
enhanc
surviv
subnanomolar
activ
lasv
use
plaqu
reduct
assay
live
viru
small
interf
rna
particl
sirna
shown
inhibit
lasv
replic
system
vitro
studi
npdirect
ldirect
sirna
demonstr
antivir
activ
lassa
vero
cell
assay
five
lassa
isol
sirna
inhibit
replic
viru
strain
log
unit
appar
effect
cell
viabil
howev
sirna
candid
must
perfectli
base
pair
target
sequenc
could
signific
roadblock
given
amount
genom
variat
lasv
monoclon
antibodi
specif
lasv
neutralis
clone
west
african
lassa
fever
survivor
appear
bind
individu
combin
lassa
gp
protein
subunit
potent
neutralis
four
lasv
lineagesan
earli
start
immunotherapeut
develop
vaccin
design
particular
recent
elucid
crystal
structur
trimer
prefus
ectodomain
lasv
gp
bound
human
neutralis
antibodi
may
acceler
develop
antibodybas
lasv
therapeut
current
vaccin
protect
lasv
vaccin
avail
use
anim
reduc
zoonot
transmiss
stimul
vaccin
develop
finalis
lassa
fever
vaccin
target
product
profil
tpp
june
made
avail
target
vaccin
scientist
product
develop
manufactur
fund
agenc
public
consult
respons
lasv
made
one
prioriti
vaccin
develop
fund
multiag
coalit
epidem
prepared
innov
cepi
use
multisector
partnership
approach
financ
develop
vaccin
infect
epidem
potenti
number
differ
platform
technolog
evalu
potenti
lassa
fever
vaccin
includ
viruslik
particl
dna
vaccin
nonrepl
inactiv
virus
lassa
yellow
fever
chimpanze
adenovir
vector
recombin
vesicular
stomat
viru
vsvlasv
reassort
viral
vector
mopvlasv
vaccin
platform
recombin
vsvlasv
reassort
consid
advanc
vaccin
candid
clinic
develop
despit
promis
preclin
evalu
none
vaccin
candid
yet
advanc
human
clinic
trial
laboratori
diagnosi
lasv
infect
made
detect
viru
cultur
lasv
rna
lasvspecif
igg
igm
antibodi
respons
lasv
antigen
shed
replic
lasv
rna
detect
use
nucleic
acid
amplif
test
includ
techniqu
pcr
loopmedi
isotherm
amplif
lamp
strand
displac
assay
antibodi
antigen
detect
indirect
immunofluoresc
assay
test
ifa
iift
western
blot
wb
elisa
rapid
diagnost
test
rdt
format
activ
infect
diagnos
viru
isol
pcr
lasv
antigen
posit
igm
along
clinic
symptom
consist
lassa
fever
diagnost
test
type
differ
complex
infrastructur
requir
appropri
rapid
respons
overview
implement
requir
rang
diagnost
avail
lasv
shown
tabl
major
intern
laboratori
use
inhous
lasv
assay
see
tabl
report
suggest
equal
number
publish
unpublish
protocol
commerci
assay
pcr
serolog
avail
primarili
label
research
use
see
onlin
supplementari
tabl
lassa
lineag
divers
must
consid
choic
pcr
primer
serolog
antigen
test
sensit
reli
homolog
unknown
specimen
molecular
probe
protein
use
detect
lineag
clade
reveal
mutat
occur
test
need
revalid
enrich
encompass
variat
observ
nucleotid
amino
acid
level
use
case
test
develop
specif
lineag
region
may
appropri
case
may
requir
detect
known
strain
bmj
global
health
specimen
divers
lasv
found
mani
bodi
fluid
compart
infect
besid
blood
includ
urin
semen
cerebrospin
fluid
evid
throat
swab
evid
acut
infect
detect
cn
report
neg
blood
lasv
persist
central
nervou
system
urin
semen
long
viral
clearanc
blood
possibl
immunolog
protect
compart
viral
titr
highli
predict
diseas
outcom
lasv
rna
detect
earli
day
infect
monkey
viral
load
peak
day
survivor
increas
death
fatal
infect
anim
patient
ill
enough
admit
hospit
averag
viral
load
serum
copi
ml
clear
within
day
survivor
patient
viral
load
copiesml
typic
progress
multiorgan
failur
shock
viremia
increas
bmj
global
health
copiesml
day
death
similar
level
found
cultur
cell
titr
tcid
ml
fatal
also
link
suppress
diminish
igm
respons
throughout
infect
support
hypothesi
earli
vigor
humor
respons
critic
surviv
infect
monkey
igg
respons
appear
late
day
postinfect
fatal
surviv
case
titr
much
higher
survivor
molecular
diagnost
molecular
diagnost
test
pcr
lamp
similar
assay
design
detect
highli
conserv
region
pathogen
genom
commonli
use
sensit
method
detect
activ
infect
molecular
diagnost
test
lasv
gener
target
genom
segment
encod
gpc
np
region
tabl
test
target
lp
genom
segment
nonspecif
old
world
arenaviru
detect
given
high
mutat
rate
genet
divers
lasv
molecular
diagnost
test
must
encompass
sequenc
divers
otherwis
risk
fals
neg
mutat
uncov
strain
amplicon
produc
older
test
sequenc
evalu
homolog
known
strain
new
probe
gener
sequenc
data
improv
lineag
sensit
case
multipl
pcr
assay
could
perform
enhanc
coverag
see
onlin
supplementari
tabl
serolog
test
use
detect
igm
igg
antibodi
rais
lasv
antigen
well
direct
captur
detect
lasv
antigen
lasv
np
gp
z
protein
shown
immunogen
igm
antigen
test
use
detect
activ
infect
although
patient
detect
igm
acut
stage
igm
igg
antibodi
immunosuppress
sever
case
particularli
endem
set
igg
gener
use
surveil
lasv
antigen
detect
demonstr
robust
method
detect
activ
infect
genet
sequenc
divers
minor
genet
mutat
typic
less
impact
protein
sequenc
earli
antigen
test
shown
variat
lasv
lineag
sensit
tandem
detect
lasv
np
antigen
antilasv
igm
demonstr
sensit
specif
earli
stage
infect
suffici
diagnosi
pcrposit
case
serolog
test
platform
lasv
includ
ifaiift
elisa
wb
multiplex
bead
assay
one
rdt
tabl
ifa
test
use
infect
vero
cell
tradit
method
lasv
serodiagnosi
larg
displac
elisa
due
time
biosafeti
constraint
serolog
test
develop
use
antigen
lasv
lineag
iv
josiah
strain
though
av
strain
also
use
small
number
elisa
kit
commerci
avail
although
primarili
market
researchus
see
onlin
supplementari
tabl
rapid
test
lasv
rdt
leverag
antibodyantigen
captur
agent
elisa
packag
strippeddown
later
flow
format
play
import
role
patient
care
outbreak
respons
outli
laboratori
clinic
dipstickbas
rdt
lasv
develop
detect
np
fingerstick
whole
blood
specimen
lasv
lineag
iv
josiah
strain
dipstick
lasv
rdt
perform
good
sensit
sensit
specif
compar
progenitor
elisa
sensit
specif
rel
qpcr
monoclon
captur
agent
develop
lasv
rdt
show
reduc
sensit
lasv
lineag
ii
iii
improv
assay
use
polyclon
approach
suggest
increas
panlineag
antigen
sensit
syndrom
approach
earli
stage
symptom
lassa
fever
mimic
endem
diseas
malaria
typhoid
fever
vhf
syndrom
approach
test
pathogen
base
syndrom
vhf
use
multiplex
panel
quickli
identifi
elimin
like
pathogen
singl
specimen
could
effect
expedit
lasv
outbreak
detect
sever
group
demonstr
multiplex
pcr
assay
differenti
detect
vhf
includ
lassa
realtim
rtpcr
assay
develop
vhf
process
reaction
reaction
overcom
limit
fluoresc
detect
combin
rtpcr
tag
primer
enabl
detect
distinct
speci
use
mass
spectrometri
other
pair
convent
assay
multiplex
detect
format
beadbas
platform
microarray
comprehens
set
taqmanbas
pcr
assay
develop
enabl
largescal
parallel
process
vhf
agent
addit
pcr
panel
febril
agent
biothreat
panel
panel
includ
lassa
commerci
avail
beadbas
realtim
taqman
format
see
onlin
supplementari
tabl
multiplex
beadbas
immunoassay
platform
differenti
diagnosi
use
antigen
igm
lassa
ebola
demonstr
greater
detect
sensit
lasv
gp
antigen
igm
respect
convent
elisa
similar
approach
use
survey
pathogen
exposur
west
africa
multiplex
igg
detect
lassa
ebola
marburg
rift
valley
fever
crimeancongo
haemorrhag
fever
well
panflaviviru
panalphaviru
challeng
lassa
diagnost
laboratorydevelop
protocol
gener
manufactur
distribut
regul
intern
agenc
remain
need
commerci
bmj
global
health
panlasv
test
assur
reproduc
qualiti
procur
intern
laboratori
agenc
ideal
lasv
diagnost
test
would
detect
known
lasv
lineag
high
sensit
pcr
enabl
sensit
platform
earli
detect
high
genet
divers
lasv
may
result
fals
neg
older
test
date
attempt
panlasv
pcr
probe
set
demonstr
antigen
test
typic
less
depend
minor
genet
mutat
earli
result
shown
variat
lineag
sensit
work
underway
demonstr
panlassa
valid
valid
qualiti
assess
valuabl
evalu
entir
test
process
includ
sampl
prepar
method
amplif
captur
detect
method
lineag
sensit
even
ident
protocol
laboratori
profici
significantli
impact
qualiti
result
extern
qualiti
assess
eqa
conduct
european
network
diagnost
import
viral
diseas
use
wellcharacteris
lassa
panel
intern
laboratori
earli
lasv
detect
rate
vari
later
improv
howev
lab
fell
goodtoaccept
perform
lab
report
falseneg
result
sourc
specimen
clinic
valid
major
roadblock
diagnost
develop
qualiti
control
intern
refer
standard
profici
panel
could
assist
develop
valid
diagnost
test
also
help
improv
laboratori
profici
eqa
effort
toward
qualiti
sever
intern
refer
institut
includ
intern
biolog
refer
custodian
laboratori
could
sourc
specimen
develop
valid
see
onlin
supplementari
list
new
diagnost
test
valid
agenc
could
assist
routin
eqa
monitor
test
perform
use
uptod
clinic
specimen
panel
refer
standard
diagnost
essenti
recognit
control
outbreak
lasv
one
widespread
genet
divers
agent
vhf
improv
lasv
test
need
endem
clinic
manag
outbreak
respons
vaccin
therapeut
clinic
trial
surveil
across
lasv
lineag
region
continu
import
rapidli
identifi
hot
spot
intervent
contain
monitor
genet
geograph
shift
human
anim
reservoir
popul
vaccin
develop
diagnost
fundament
detect
differenti
infect
challeng
vaccin
immun
final
strong
consensu
earli
diagnosi
treatment
increas
surviv
rate
lasv
infect
review
identifi
test
resourc
lassa
molecular
diagnost
serolog
describ
larg
number
inhous
lasv
test
use
across
intern
commun
howev
sever
gap
identifi
r
blueprint
remain
effort
made
advanc
exist
diagnost
platform
toward
clinic
valid
regulatori
approv
implement
diagnost
could
refin
detail
understand
lasv
kinet
across
rang
sampl
type
robust
pointofcar
fieldappropri
design
appropri
test
current
avail
could
benefit
eqa
goal
standardis
test
sensit
specif
lineageregion
coverag
given
challeng
identifi
lasv
detect
endem
often
lowresourc
set
rapid
onsit
diagnosi
suspect
case
may
bridg
gap
rang
assay
alreadi
develop
commerci
pointofcar
platform
thu
possibl
current
lasv
assay
could
adapt
cartridgebas
format
combin
rapid
pointofcar
antigen
detect
pointofcar
confirmatori
test
suggest
ideal
implement
earli
case
detect
outbreak
respons
aforement
diagnost
use
scenario
differ
perform
requir
text
complex
sensit
specif
turnaround
time
develop
new
improv
lasv
diagnost
could
facilit
clearli
defin
set
use
case
describ
diagnost
test
need
coupl
tpp
detail
perform
characterist
highest
prioriti
molecular
immunodiagnost
numer
barrier
achiev
regulatori
approv
exist
initi
organis
foundat
innov
new
diagnost
find
cepi
intend
make
develop
commercialis
lasv
diagnost
feasibl
contributor
ltm
contribut
draft
manuscript
provid
background
research
manuscript
ckc
contribut
insight
diagnost
need
outbreak
pathogen
author
review
edit
approv
final
version
manuscript
fund
find
fund
work
uk
aid
uk
govern
disclaim
opinion
express
articl
author
necessarili
reflect
institut
organis
affili
compet
interest
none
declar
patient
consent
requir
proven
peer
review
commiss
extern
peer
review
open
access
open
access
articl
distribut
accord
creativ
common
attribut
unport
cc
licens
permit
other
copi
redistribut
remix
transform
build
upon
work
purpos
provid
origin
work
properli
cite
link
licenc
given
indic
whether
chang
made
see
http
creativecommon
org
licens
